Contact Us
join our enewsletter  |   translate
Donate
Print Page    A A

Mavrilimumab

Status
Phase 2
Condition
COVID-19
Intervention Type
Intravenous (IV) Injection
Funder Type
Organization | University

Drug Details

Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor.

Study Purpose

The primary endpoint of this study is to assess the effects of a single IV dose of mavrilimumab on the acute inflammatory response in patients with severe COVID-19 pneumonia.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >


The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

Charity Navigator 4 star     better business bureau logo      NHCSEP_PFF      Giving Star

PRIVACY POLICY    TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation   |   230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741   |   f. 866.587.9158   |   info@pulmonaryfibrosis.org
Join Our Monthly eNewsletter

PRIVACY POLICY    TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation   |   230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741   |   f. 866.587.9158   |   info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.